Literature DB >> 3102381

Activation of murine macrophages and a bovine monocyte cell line by bovine lymphokines to kill the intracellular pathogens Eimeria bovis and Toxoplasma gondii.

H P Hughes, C A Speer, J E Kyle, J P Dubey.   

Abstract

Macrophage (M phi)-activating lymphokines present in concanavalin A-stimulated bovine T-lymphocyte cultures (ConAS) were studied by assessing their effects on Eimeria bovis and Toxoplasma gondii growth in cultured bovine monocytes (BM) and mouse M phi. The in vitro development of both parasites was assessed by incorporation of [3H]uracil and by microscopic examination of parallel cultures. Incorporation of [3H]uracil into infected cultures was an accurate indicator of growth of both E. bovis and T. gondii in BM and mouse M phi. Sporozoites of E. bovis underwent merogony in untreated BM but not in mouse M phi, whereas T. gondii developed in both cell types. Inhibition of T. gondii growth was greatest in ConAS-treated BM, whereas preincubation of mouse M phi with ConAS resulted in about 80% growth inhibition. There was no significant difference between the inhibition of either T. gondii sporozoite- or tachyzoite-induced growth in ConAS-treated cells, showing that activation pathways are equally effective against both stages. Treatment of ConAS with glycine-hydrochloride buffer (pH 2) resulted in a total loss of antiviral activity mediated by gamma interferon (IFN-gamma). When pH 2 dialyzed ConAS was used to activate BM, inhibition of T. gondii growth was only partially affected. Because bovine IFN-gamma does not activate mouse M phi and due to the partial effects of pH 2 on ConAS-induced growth inhibition, the major component(s) of ConAS responsible for T. gondii growth inhibition is distinct from IFN-gamma. Furthermore, IFN-gamma may act synergistically rather than being part of a priming sequence for M phi responsiveness to other lymphokines. Murine recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) was tested for any microbistatic activity against T. gondii sporozoites and tachyzoites. There was no significant difference in either colony formation or [3H]uracil incorporation between rGM-CSF-treated and control cultures, regardless of host cell type. Thus, rGM-CSF does not induce adequate M phi activation to kill T. gondii and is not a major microbistatic component of ConAS. rGM-CSF also had no effect on T. gondii infection in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102381      PMCID: PMC260411          DOI: 10.1128/iai.55.3.784-791.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Induction of resistance to Toxoplasma gondii in human macrophages by soluble lymphocyte products.

Authors:  S E Anderson; S Bautista; J S Remington
Journal:  J Immunol       Date:  1976-08       Impact factor: 5.422

2.  A role for activated macrophages in resistance to infection with Toxoplasma.

Authors:  J S Remington; J L Krahenbuhl; J W Mendenhall
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

3.  Loss of stages after continuous passage of Toxoplasma gondii and Besnoitia jellisoni.

Authors:  J K Frenkel; J P Dubey; R L Hoff
Journal:  J Protozool       Date:  1976-08

4.  A new soluble antigen preparation of Toxoplasma gondii and its use in serological diagnosis.

Authors:  H P Hughes; F Van Knapen; H J Atkinson; A H Balfour; D L Lee
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

5.  Ultrastructure of excystment of Toxoplasma gondii oocysts.

Authors:  E Christie; P W Pappas; J P Dubey
Journal:  J Protozool       Date:  1978-11

6.  A method to evaluate the capacity of monocytes and macrophages to inhibit multiplication of an intracellular pathogen.

Authors:  R McLeod; J S Remington
Journal:  J Immunol Methods       Date:  1979-05-10       Impact factor: 2.303

7.  Some physicochemical characteristics of an immune lymphocyte product which inhibits the multiplication of toxoplasma within mouse macrophages.

Authors:  T Shirahata; K Shimizu
Journal:  Microbiol Immunol       Date:  1979       Impact factor: 1.955

8.  Production and properties of Toxoplasma growth inhibitory factor (Toxo-GIF) and interferon (IFN) in the lymphokines and the circulation of Toxoplasma immune mice.

Authors:  H Sakurai; Y Takei; Y Omata; N Suzuki
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1981-12

9.  Distribution of Toxoplasma gondii tissue cysts in commercial cuts of pork.

Authors:  J P Dubey; K D Murrell; R Fayer; G A Schad
Journal:  J Am Vet Med Assoc       Date:  1986-05-01       Impact factor: 1.936

10.  Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.

Authors:  J L Pace; S W Russell; B A Torres; H M Johnson; P W Gray
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

View more
  5 in total

Review 1.  Avian gut-associated lymphoid tissues and intestinal immune responses to Eimeria parasites.

Authors:  H S Lillehoj; J M Trout
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

2.  Cytokine mRNA in the central nervous system of SCID mice infected with Toxoplasma gondii: importance of T-cell-independent regulation of resistance to T. gondii.

Authors:  C A Hunter; J S Abrams; M H Beaman; J S Remington
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

3.  Gamma interferon-mediated inhibition of Eimeria vermiformis growth in cultured fibroblasts and epithelial cells.

Authors:  M E Rose; A L Smith; D Wakelin
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

4.  Effects of immunosuppression on avian coccidiosis: cyclosporin A but not hormonal bursectomy abrogates host protective immunity.

Authors:  H S Lillehoj
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

5.  Antigen-specific lymphocyte transformation induced by oocyst antigens of Eimeria bovis.

Authors:  H P Hughes; K R Thomas; C A Speer
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.